Intellectual Property India Publishes Patent Application for 'Crispr-Mediated Gene Editing To Induce Fetal Hemoglobin' Filed by Micro Crispr Pvt. Ltd.

MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202421004086 A) filed by Micro Crispr Pvt. Ltd., Vapi, Gujarat, on Feb. 19, 2024, for 'crispr-mediated gene editing to induce fetal hemoglobin.'

Inventor(s) include Bhargava, Nupur; Vyas, Jitendra; and Bilakhia, Aaman.

The application for the patent was published on Aug. 22, under issue no. 34/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure discloses a gene editing system (100) to induce expression of fetal hemoglobin (HbF) in hematopoietic stem cells (HSCs). The gene editing system (100) includes a guide RNA (gRNA 110) extending between a 5'end and a 3' end, and an endonuclease (120). The gRNA (110) includes at least one Crispr RNA (crRNA) (110a) disposed towards the 5' end of the gRNA (110) and a trans-activating Crispr RNA (tracrRNA) (110b) disposed towards the 3' end of the gRNA (110). The crRNA (110a) is encoded by at least one of SEQ ID NO. 1 - 6. The crRNA (110a) is configured to bind a target strand at a pre-defined locus of a genomic DNA (gDNA) (10). The endonuclease (120) is coupled to the gRNA (110) via the tracrRNA (110b). The endonuclease (120) is configured to introduce a double-strand break (DSB) in the gDNA (10)."

Disclaimer: Curated by HT Syndication.